Technology Appraisal Committee Meeting (Committee D)

Minutes: Unconfirmed

Date and Time: Wednesday 27 July 2016 10:15 – 17:00
Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Professor Gary McVeigh, Chair Present for all notes
2. Dr Lindsay Smith, Vice Chair Present for all notes
3. Dr Andrew Black Present for all notes
4. Dr Aomesh Bhatt Present for all notes
5. Dr Matthew Bradley Present for all notes
6. Ms Tracey Cole Present for all notes
7. Dr Ian Davidson Present for all notes
8. Professor Simon Dixon Present for all notes
9. Mrs Susan Dutton Present for all notes
10. Dr Alexander Dyker Present for all notes
11. Mrs Gillian Ells Present for all notes
12. Dr Susan Griffin Present for all notes
13. Professor Carol Haigh Present for all notes
14. Professor John Henderson Present for all notes
15. Mr Malcolm Oswald Present for all notes
16. Professor Oluwafemi Oyebode Present for all notes
17. Dr Mohit Sharma Present for all notes

In attendance:
Maiwenn Al Kleijnen Systematic Reviews Ltd (KSR) Present for notes 01 to 09
Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes 01 to 19
Professor Graham Foster NHS commissioning expert, nominated by NHS England Present for notes 01 to 09
Rob Riemsma Kleijnen Systematic Reviews Ltd (KSR) Present for notes 01 to 09
Ahmad Abdulla Research Associate, Liverpool Reviews and Implementation Group (LRIG) Present for notes 10 to 14
Professor Adrian Bagust Liverpool Reviews and Implementation Group Present for notes 10 to 14
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Sanjay Bhagani (LRIG)</td>
<td>ERG representative Aberdeen HTA Group</td>
<td>Present for notes 01 to 11</td>
</tr>
<tr>
<td>Dr Angela Boland</td>
<td>Associate Director, Liverpool Reviews and Implementation Group (LRIG)</td>
<td>Present for notes 15 to 19</td>
</tr>
<tr>
<td>Nasuh Büyükkaramikl</td>
<td>Health Economic Researcher, Kleijnen Systematic Reviews Ltd (KSR)</td>
<td>Present for notes 01 to 09</td>
</tr>
<tr>
<td>Diane Dobson</td>
<td>Patient expert, Pancreatic Cancer UK</td>
<td>Present for notes 01 to 14</td>
</tr>
<tr>
<td>Sally Doss</td>
<td>Technical Advisor, National Institute for Health and Care Excellence</td>
<td>Present for notes 01 to 19</td>
</tr>
<tr>
<td>Nigel Fleeman</td>
<td>Research Fellow, LRiG</td>
<td>Present for notes 10 to 14</td>
</tr>
<tr>
<td>Professor Anna Maria Geretti</td>
<td>Clinical expert, nominated by Gilead</td>
<td>Present for notes 01 to 09</td>
</tr>
<tr>
<td>Dr Christian Griffiths</td>
<td>Technical Lead, National Institute for Health and Care Excellence</td>
<td>Present for notes 15 to 19</td>
</tr>
<tr>
<td>Rachel Halford</td>
<td>Patient expert, Hepatitis C Trust</td>
<td>Present for notes 01 to 09</td>
</tr>
<tr>
<td>Caroline Hall</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for notes 10 to 14</td>
</tr>
<tr>
<td>Helen Knight</td>
<td>Associate Director, National Institute for Health and Care Excellence</td>
<td>Present for all notes 01 to 19</td>
</tr>
<tr>
<td>James Mahon</td>
<td>Liverpool Reviews and Implementation Group (LRIG)</td>
<td>Present for notes 15 to 19</td>
</tr>
<tr>
<td>Kelvin Marshall</td>
<td>Patient expert, Liver 4 Life</td>
<td>Present for notes 01 to 09</td>
</tr>
<tr>
<td>Dr Mairéad McNamara</td>
<td>Senior lecturer and Honorary Consultant in Medical Oncology Nominated by Shire</td>
<td>Present for notes 10 to 14</td>
</tr>
<tr>
<td>Kate Moore</td>
<td>Project Manager, National Institute for Health and Care Excellence</td>
<td>Present for all notes 01 to 19</td>
</tr>
<tr>
<td>Dr John Nathan</td>
<td>Patient expert, Pancreatic Cancer UK</td>
<td>Present for notes 10 to 14</td>
</tr>
<tr>
<td>Paula O’Grady</td>
<td>National Institute for Health and Care Excellence</td>
<td>Present for all notes 01 to 19</td>
</tr>
<tr>
<td>Professor Pieter Postmus</td>
<td>Consultant, nominated by Royal College of Physicians</td>
<td>Present for notes 15 to 19</td>
</tr>
</tbody>
</table>
Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of elbasvir-grazoprevir for treating chronic hepatitis C. Pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine and Osimertinib for treating metastatic EGFR and T790M mutation-positive non-small-cell lung cancer.

2. The Chair informed the Committee of the non-public observers at this meeting: Sumeet Gupta, Sumithra Maheswaran, Jessica Maloney, Helen Powell and Hiral Shah.

3. Apologies were received from Dr Andrew Black, Dr Ian Campbell, Professor Paula Ghaneh, Dr Tim Kinnaird and Dr Paula Parvulescu.

Any other Business

4. None

Appraisal of elbasvir-grazoprevir for treating chronic hepatitis C [ID842]

Part 1 – Open session

5. The Chair welcomed the invited experts: Dr Sanjay Bhagani, Professor Anna Maria Geretti, Rachel Halford and Kelvin Marshall to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Merck Sharp & Dohme to the meeting.

7. The Chair asked all Committee members to declare any relevant interests.
7.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Aomesh Bhatt, Dr David Bowen, Dr Matthew Bradley, Ms Tracey Cole, Dr Ian Davidson, Professor Simon Dixon, Mrs Susan Dutton, Dr Alexander Dyker, Mrs Gillian Ells, Dr Susan Griffin, Professor John Henderson, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, Dr Mohit Sharma all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of elbasvir-grazoprevir for treating chronic hepatitis C.

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of elbasvir-grazoprevir for treating chronic hepatitis C.

9. The Chair asked all other invited guests to declare their relevant interests.

9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of elbasvir-grazoprevir for treating chronic hepatitis C.

10. The Chair introduced the lead team, Dr Matthew Bradley, Ms Tracey Cole and Professor John Henderson who gave presentations on the clinical effectiveness and cost effectiveness of elbasvir-grazoprevir for treating chronic hepatitis C.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. The Committee continued to discuss the clinical and cost effectiveness of elbasvir-grazoprevir for treating chronic hepatitis C.

14.1. The committee decision was based on consensus.
15. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine [ID778]

Part 1 – Open session

16. The Chair welcomed company representatives from Shire to the meeting.

17. The Chair asked all Committee members to declare any relevant interests

17.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Aomesh Bhatt, Dr David Bowen, Dr Matthew Bradley, Ms Tracey Cole, Dr Ian Davidson, Professor Simon Dixon, Mrs Susan Dutton, Dr Alexander Dyker, Mrs Gillian Ells, Dr Susan Griffin, Professor John Henderson, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, Dr Mohit Sharma all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine.

18. The Chair asked all NICE Staff to declare any relevant interests.

18.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine.

19. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

20. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

21. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

22. The Committee continued to discuss the clinical and cost effectiveness of pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine.
22.1. The committee decision was based on consensus.

23. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Appraisal of osimertinib for treating metastatic EGFR and T790M mutation-positive non-small-cell lung cancer [ID874]**

**Part 1 – Open session**

24. The Chair welcomed company representatives from AstraZeneca to the meeting.

25. The Chair asked all Committee members to declare any relevant interests

25.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Aomesh Bhatt, Dr David Bowen, Dr Matthew Bradley, Ms Tracey Cole, Dr Ian Davidson, Professor Simon Dixon, Mrs Susan Dutton, Dr Alexander Dyker, Mrs Gillian Ells, Dr Susan Griffin, Professor John Henderson, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, Dr Mohit Sharma all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of osimertinib for treating metastatic EGFR and T790M mutation-positive non-small-cell lung cancer.

26. The Chair asked all NICE Staff to declare any relevant interests.

26.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of osimertinib for treating metastatic EGFR and T790M mutation-positive non-small-cell lung cancer.

27. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

28. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

29. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
Part 2 – Closed session

30. The Committee continued to discuss the clinical and cost effectiveness of osimertinib for treating metastatic EGFR and T790M mutation-positive non-small-cell lung cancer.

30.1 The committee decision was based on consensus.

31. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

32. Thursday 25 August 2016, 10:00 – 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.